Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials
In two pivotal efficacy studies (ZOE-50; ZOE-70), the adjuvanted recombinant zoster vaccine (RZV) demonstrated >90% efficacy against herpes zoster (HZ). Adults aged ≥50 or ≥70 years (ZOE-50 [NCT01165177]; ZOE-70 [NCT01165229]) were randomized to receive 2 doses of RZV or placebo 2 months apart. V...
Salvato in:
Autori principali: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Natura: | Libro |
Pubblicazione: |
Taylor & Francis Group,
2019-12-01T00:00:00Z.
|
Soggetti: | |
Accesso online: | Connect to this object online. |
Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
Accesso online
Connect to this object online.3rd Floor Main Library
Collocazione: |
A1234.567 |
---|---|
Copia 1 | Disponibile |